MLH1, BRAF and P53 - Searching for Significant Markers to Predict Evolution Towards Adenocarcinoma in Colonic Sessile Serrated Lesions

Overview

Journal Rom J Morphol Embryol

Specialties Anatomy & Histology
Cell Biology
Reproductive Medicine

Date 2022 Jun 8

PMID 35673816

Authors

Diana Raduta

Octavian Marius Dinca

Gianina Viorica Micu

Luciana Nichita

Mirela Daniela Cioplea

Radu Mihai Busca

Raluca Ardeleanu

Radu Bogdan Mateescu

Andreea Bengus

Sabina Andrada Zurac

Cristiana Gabriela Popp

George Cristian Vladan

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Colonic serrated lesions are premalignant lesions, using an alternative malignization pathway, including multiple genetic and epigenetic alterations, as: mismatch repair deficiency due to MutL homolog 1 (MLH1) promoter methylation, tumor protein p53 (TP53) mutations, activating mutations of v-Raf murine sarcoma viral oncogene homolog B (BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS). Our study aims to evaluate MLH1, BRAF and p53 immunohistochemical (IHC) status in sessile serrated lesions (SSLs), with and without dysplasia.

Materials And Methods: This is a retrospective case-control study including 20 SSLs with dysplasia and 20 SSLs without dysplasia (matching sex and age). IHC expression of MLH1, BRAF and p53 was evaluated as the percent of nuclear loss of MLH1, cytoplasmic positivity of BRAF and nuclear positivity of p53. Data concerning age, sex, localization of the lesion, dysplasia and IHC results were statistically processed using Microsoft Excel.

Results: We had very polymorphous patterns of IHC expression for BRAF, MLH1 and p53, especially in the dysplastic group. Thus, two patients were BRAF+∕MLH1-∕p53+, three were BRAF+∕MLH1-∕p53-, one was BRAF+∕MLH1+∕p53- and six were BRAF+∕MLH1+∕p53+. Dysplastic lesions without BRAF mutation exhibited the following phenotype: one case BRAF-∕MLH1-∕p53+, four BRAF-∕MLH1-∕p53- and three BRAF-∕MLH1+∕p53+. In the control group (SSLs without dysplasia), there was a more homogenous distribution of cases: eight cases BRAF+∕MLH1+∕p53-, seven BRAF-∕MLH1+∕p53-, one BRAF-∕MLH1-∕p53+, two BRAF-∕MLH1-∕p53- and two BRAF-∕MLH1+∕p53+.

Conclusions: There are more routes on the serrated pathway, with different mutations and time of acquisition of each genetic or epigenetic lesion with the same morphological result. These lesions should be stratified according to their risk to poor outcome and their need to further surveillance.

Citing Articles

Comparative Expression Analysis of Tumor Suppressor and Oncogene in Colorectal Adenocarcinoma.

Niotis A, Dimitroulis D, Spyropoulou D, Tsiambas E, Sarlanis H, Davris D Cancer Diagn Progn. 2024; 4(2):129-134.

PMID: 38434910 PMC: 10905287. DOI: 10.21873/cdp.10298.

The histopathological features and their prognostic impact in the postoperative follow-up of colorectal cancer patients.

Patrascu S, Cercelaru L, Graure G, Firut M, Rotaru I, Cartu D Rom J Morphol Embryol. 2023; 63(3):555-561.

PMID: 36588494 PMC: 9926144. DOI: 10.47162/RJME.63.3.10.

Clinical and morphopathological assay in vulvovaginal candidiasis.

Manolea M, Istrate-Ofiteru A, Sandulescu M, Camen I, Piciu I, Dijmarescu A Rom J Morphol Embryol. 2023; 63(3):511-520.

PMID: 36588489 PMC: 9926141. DOI: 10.47162/RJME.63.3.05.

References

Borowsky J, Dumenil T, Bettington M, Pearson S, Bond C, Fennell L . The role of APC in WNT pathway activation in serrated neoplasia. Mod Pathol. 2017; 31(3):495-504. DOI: 10.1038/modpathol.2017.150. View

Burgess N, Tutticci N, Pellise M, Bourke M . Sessile serrated adenomas/polyps with cytologic dysplasia: a triple threat for interval cancer. Gastrointest Endosc. 2014; 80(2):307-10. DOI: 10.1016/j.gie.2014.03.050. View

Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R . Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013; 105(15):1151-6. PMC: 3735463. DOI: 10.1093/jnci/djt173. View

Murakami T, Akazawa Y, Yatagai N, Hiromoto T, Sasahara N, Saito T . Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study. Diagn Pathol. 2018; 13(1):88. PMC: 6247685. DOI: 10.1186/s13000-018-0771-3. View

Sweetser S, Smyrk T, Sugumar A . Serrated polyps: critical precursors to colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011; 5(5):627-35. DOI: 10.1586/egh.11.67. View

Murakami T, Sakamoto N, Ritsuno H, Shibuya T, Osada T, Mitomi H . Distinct endoscopic characteristics of sessile serrated adenoma/polyp with and without dysplasia/carcinoma. Gastrointest Endosc. 2016; 85(3):590-600. DOI: 10.1016/j.gie.2016.09.018. View

Anderson J, Lisovsky M, Greene M, Hagen C, Srivastava A . Factors Associated With Classification of Hyperplastic Polyps as Sessile Serrated Adenomas/Polyps on Morphologic Review. J Clin Gastroenterol. 2017; 52(6):524-529. DOI: 10.1097/MCG.0000000000000840. View

Kim J, Kang G . Evolving pathologic concepts of serrated lesions of the colorectum. J Pathol Transl Med. 2020; 54(4):276-289. PMC: 7385269. DOI: 10.4132/jptm.2020.04.15. View

Sandouk F, Al Jerf F, Al-Halabi M . Precancerous lesions in colorectal cancer. Gastroenterol Res Pract. 2013; 2013:457901. PMC: 3666221. DOI: 10.1155/2013/457901. View

10.

Nakanishi Y, Diaz-Meco M, Moscat J . Serrated Colorectal Cancer: The Road Less Travelled?. Trends Cancer. 2019; 5(11):742-754. PMC: 6894428. DOI: 10.1016/j.trecan.2019.09.004. View

11.

McCarthy A, OReilly S, Shanley J, Geraghty R, Ryan E, Cullen G . Colorectal Serrated Neoplasia: An Institutional 12-Year Review Highlights the Impact of a Screening Programme. Gastroenterol Res Pract. 2019; 2019:1592306. PMC: 6381559. DOI: 10.1155/2019/1592306. View

12.

Sano W, Hirata D, Teramoto A, Iwatate M, Hattori S, Fujita M . Serrated polyps of the colon and rectum: Remove or not?. World J Gastroenterol. 2020; 26(19):2276-2285. PMC: 7243646. DOI: 10.3748/wjg.v26.i19.2276. View

13.

Burgess N, Pellise M, Nanda K, Hourigan L, Zanati S, Brown G . Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps. Gut. 2015; 65(3):437-46. DOI: 10.1136/gutjnl-2014-308603. View

14.

Sano W, Fujimori T, Ichikawa K, Sunakawa H, Utsumi T, Iwatate M . Clinical and endoscopic evaluations of sessile serrated adenoma/polyps with cytological dysplasia. J Gastroenterol Hepatol. 2018; 33(8):1454-1460. DOI: 10.1111/jgh.14099. View

15.

Clarke C, Kopetz E . BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015; 6(6):660-7. PMC: 4671844. DOI: 10.3978/j.issn.2078-6891.2015.077. View

16.

Kane A, Fennell L, Liu C, Borowsky J, McKeone D, Bond C . Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of BRAF mutant microsatellite stable colorectal cancer. Neoplasia. 2020; 22(2):120-128. PMC: 6961716. DOI: 10.1016/j.neo.2019.12.002. View

17.

Hashimoto T, Yamashita S, Yoshida H, Taniguchi H, Ushijima T, Yamada T . WNT Pathway Gene Mutations Are Associated With the Presence of Dysplasia in Colorectal Sessile Serrated Adenoma/Polyps. Am J Surg Pathol. 2017; 41(9):1188-1197. DOI: 10.1097/PAS.0000000000000877. View

18.

De Palma F, DArgenio V, Pol J, Kroemer G, Maiuri M, Salvatore F . The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678087. DOI: 10.3390/cancers11071017. View

19.

Kedrin D, Gala M . Genetics of the serrated pathway to colorectal cancer. Clin Transl Gastroenterol. 2015; 6:e84. PMC: 4459531. DOI: 10.1038/ctg.2015.12. View

20.

Satorres C, Garcia-Campos M, Bustamante-Balen M . Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future Directions. Gut Liver. 2020; 15(1):31-43. PMC: 7817929. DOI: 10.5009/gnl19402. View